CSIMarket
 


Painreform Ltd  (PRFX)
Other Ticker:  
 
 

PRFX's Net Income Growth by Quarter and Year

Painreform Ltd's Net Income results by quarter and year




PRFX Net Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December -8.79 -7.25 0.00 0.00
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   -8.79 -7.25 0.00 0.00



PRFX Net Income fourth quarter 2022 Y/Y Growth Comment
Painreform Ltd in the fourth quarter 2022 recorded net loss of $ -8.79 millions.

According to the results reported in the fourth quarter 2022, Painreform Ltd achieved the best Net Income growth in Major Pharmaceutical Preparations industry. While Painreform Ltd' s Net Income no change of % ranks overall at the positon no. in the fourth quarter 2022.




PRFX Net Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Painreform Ltd's fourth quarter 2022 Net Income $ -8.79 millions PRFX's Income Statement
Painreform Ltd's fourth quarter 2021 Net Income $ -7.25 millions Quarterly PRFX's Income Statement
New: More PRFX's historic Net Income Growth >>


PRFX Net Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Net Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Net Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Net Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Painreform Ltd's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PRFX's IV. Quarter Q/Q Net Income Comment


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #
Net Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


PRFX's IV. Quarter Q/Q Net Income Comment


Painreform Ltd's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
0
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
Cumulative Net Income 12 Months Ending $ -8.79 $ 0.00 $ 0.00 $ 0.00 $ -7.25
Y / Y Net Income Growth (TTM) - - - - -
Year on Year Net Income Growth Overall Ranking # # # # #
Seqeuential Net Income Change (TTM) - - - - -
Seq. Net Income Growth (TTM) Overall Ranking # # # # #




Cumulative Net Income growth Comment
Painreform Ltd' has realized cumulative trailing twelve months net loss of $ -9 millions in the Dec 31 2022 period.
The situation is getting worse as the cumulative net loss is becoming larger from $ -7.25 millions for the period from 0 to Dec 31 2021 and $ millions from the TTM period ending Dec 31 2021.

Painreform Ltd achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Net Income growth Comment
Painreform Ltd' has realized cumulative trailing twelve months net loss of $ -9 millions in the Dec 31 2022 period.
The situation is detiriorating as the cumulative net loss is inflating from $ -7.25 millions for the period from 0 to Dec 31 2021 and $ millions for the twelve months ending in the quarter Dec 31 2021.

Painreform Ltd achieved highest trailing twelve month year on year Net Income growth. While overall Net Income growth ranking, remained unchanged compare to the previous quarter at no. .

Net Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Net Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
PRFX's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for PRFX's Competitors
Net Income Growth for Painreform Ltd's Suppliers
Net Income Growth for PRFX's Customers

You may also want to know
PRFX's Annual Growth Rates PRFX's Profitability Ratios PRFX's Asset Turnover Ratio PRFX's Dividend Growth
PRFX's Roe PRFX's Valuation Ratios PRFX's Financial Strength Ratios PRFX's Dividend Payout Ratio
PRFX's Roa PRFX's Inventory Turnover Ratio PRFX's Growth Rates PRFX's Dividend Comparisons



Companies with similar Net Income no change for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Net Income for the quarter ending Dec 31 2022
Carlisle Companies Incorporated35.99%$ 35.988 millions
Charles River Laboratories International inc 35.24%$ 35.243 millions
Dr Reddy s Laboratories Limited31.78%$ 31.780 millions
Vericel Corporation30.58%$ 30.584 millions
Elite Pharmaceuticals Inc 30.07%$ 30.072 millions
Bruker Corporation29.34%$ 29.342 millions
Cadre Holdings inc 24.37%$ 24.369 millions
Alpha Tau Medical Ltd 23.80%$ 23.802 millions
Ensign Group Inc23.61%$ 23.607 millions
Neurocrine Biosciences Inc 22.25%$ 22.253 millions
Staar Surgical Company18.92%$ 18.915 millions
Edwards Lifesciences Corporation18.82%$ 18.819 millions
Purple Biotech Ltd 17.83%$ 17.825 millions
United Therapeutics Corporation17.74%$ 17.736 millions
Integra Lifesciences Holdings Corp16.66%$ 16.662 millions
Electromed Inc 16.59%$ 16.587 millions
Mettler Toledo International Inc15.14%$ 15.144 millions
Option Care Health Inc 14.98%$ 14.979 millions
Addus Homecare Corporation13.05%$ 13.049 millions
Eli Lilly And Company12.26%$ 12.259 millions
Resmed Inc 11.48%$ 11.481 millions
Zoetis Inc 11.38%$ 11.380 millions
Check cap Ltd 11.08%$ 11.080 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com